Plasma lipid and lipoprotein disorders in IDDM

Area of Science:

• Endocrinology
• Metabolic Disorders
• Cardiovascular Science

Background:

• Abnormal lipoprotein metabolism is linked to premature atherosclerosis in type 1 diabetes.
• While conventional insulin therapy normalizes fasting lipids, intensive therapy doesn't resolve lipoprotein composition changes.
• Peripheral hyperinsulinemia from subcutaneous insulin therapy is implicated in these persistent lipoprotein alterations.

Purpose of the Study:

• To investigate the impact of intraperitoneal (i.p.) insulin delivery on lipoprotein metabolism in insulin-dependent diabetes (IDDM).
• To assess whether i.p. insulin therapy can mitigate lipoprotein composition changes associated with subcutaneous (s.c.) insulin therapy.
• To determine if peripheral hyperinsulinemia contributes to altered lipoprotein metabolism in IDDM.

Main Methods:

• Utilizing implantable insulin-infusion pumps for i.p. insulin delivery in IDDM patients.
• Comparing lipoprotein profiles and composition between i.p. and s.c. insulin therapy groups.
• Monitoring plasma glucose levels and peripheral insulin levels.

Main Results:

• i.p. insulin therapy effectively maintains near-normal plasma glucose levels.
• i.p. insulin therapy reduces peripheral hyperinsulinemia compared to s.c. therapy.
• Studies on i.p. insulin therapy's effects on lipoprotein metabolism have yielded contradictory results thus far.

Conclusions:

• i.p. insulin therapy presents a potential method to reduce peripheral hyperinsulinemia in IDDM.
• Further research is needed to clarify the role of peripheral hyperinsulinemia in IDDM-related lipoprotein alterations.
• i.p. insulin therapy's impact on lipoprotein metabolism requires more investigation to resolve existing contradictions.